RE:RE:RE:ONCY's pelareorep enables CAR-T trafficking in solid tumors"
Overall Survival Isn’t Everything
In November 2023, the agency delayed approval of Abecma for earlier treatment and announced an upcoming advisory committee meeting. That same month, the FDA revealed that CAR-T therapies were under review after several reports of secondary blood cancers in treated patients, and in January, the agency added a class warning to all six currently approved CAR-T therapies."
And according to Rahul Banerjee, a physician-researcher specializing in multiple myeloma at the Fred Hutchinson Cancer Center in Seattle, Wash. when it comes to CAR-T therapy, the lines of therapy concept may be outdated. Whether or not the approach makes sense is a topic of conversation at meetings and conferences, he said, noting that a line of therapy can be different from a treatment regimen. For example, “if the dose of a medication is lowered, it is not considered a new line,” he explained. “It’s a little bit arbitrary.”